• Issue

    Pharmacoepidemiology and Drug Safety: Volume 31, Issue 7

    717-816
    July 2022
Previous Issue|Next Issue
Export Citation(s)Download PDF(s)

ISSUE INFORMATION

Free Access

Issue Information

  • First Published: 07 June 2022

COMMENTARY

Open Access

Real-world data: Assessing electronic health records and medical claims data to support regulatory decision-making for drug and biological products

Cynthia J. Girman,  Mary E. Ritchey,  Vincent Lo Re III, 
  • Pages: 717-720
  • First Published: 26 April 2022

ORIGINAL ARTICLES

Categorization of COVID-19 severity to determine mortality risk

Elizabeth M. Garry,  Andrew R. Weckstein,  Kenneth Quinto,  Marie C. Bradley,  Tamar Lasky,  Aloka Chakravarty,  Sandy Leonard,  Sarah E. Vititoe,  Imaani J. Easthausen,  Jeremy A. Rassen,  Nicolle M. Gatto, 
  • Pages: 721-728
  • First Published: 04 April 2022

A risk classification model for prioritising the management of quality issues relating to substandard medicines in Singapore

Pei San Ang,  Desmond Chun Hwee Teo,  Yi Long Toh,  Michelle Sau Yuen Ng,  Chih Tzer Choong,  Doris Sock Tin Phuah,  Dorothy Hooi Myn Tan,  Filina Meixuan Tan,  Maggie Siok Hwee Tan,  Suan Tian Koh,  Wint Maw Thinn,  Jalene Wang Woon Poh,  Sreemanee Raaj Dorajoo, 
  • Pages: 729-738
  • First Published: 02 April 2022
Open Access

How measurements affected by medication use are reported and handled in observational research: A literature review

Jungyeon Choi,  Olaf M. Dekkers,  Saskia le Cessie, 
  • Pages: 739-748
  • First Published: 05 April 2022
Open Access

Antibiotic use in children before, during and after hospitalisation

Christian Magnus Thaulow,  Hege Salvesen Blix,  Roy Miodini Nilsen,  Beate Horsberg Eriksen,  Jannicke Slettli Wathne,  Dag Berild,  Stig Harthug, 
  • Pages: 749-757
  • First Published: 05 April 2022
Open Access

A cross-sectional survey to evaluate prescribers' knowledge and understanding of safety messages following Dengvaxia® product information update

Mariana F. Almas,  Massoud Toussi,  Elisa Valero,  Annick Moureau,  Lydie Marcelon, 
  • Pages: 758-768
  • First Published: 03 May 2022

Evaluating the population-level effects of oxycodone restrictions on prescription opioid utilization in Ontario

David Rudoler,  Paul Kurdyak,  Tara Gomes,  Anjie Huang,  Wayne Jones,  Stephanie Littleford,  Nabiha Paracha,  Benedikt Fischer, 
  • Pages: 769-778
  • First Published: 26 April 2022
Open Access

International trends in prescription opioid sales among developed and developing economies, and the impact of the COVID-19 pandemic: A cross-sectional analysis of 66 countries

Tara Gomes,  Katherine Callaway Kim,  Katie J. Suda,  Ria Garg,  Mina Tadrous, 
  • Pages: 779-787
  • First Published: 23 April 2022

Applying mixture cure survival modeling to medication persistence analysis

Chao Cai,  Bryan L. Love,  Ismaeel Yunusa,  Claiborne E. Reeder, 
  • Pages: 788-795
  • First Published: 14 April 2022

Alternative analytic and matching approaches for the prevalent new-user design: A simulation study

Michael Webster-Clark,  Panagiotis Mavros,  Elizabeth M. Garry,  Til Stürmer,  Shahar Shmuel,  Jessica Young,  Cynthia Girman, 
  • Pages: 796-803
  • First Published: 03 May 2022

BRIEF REPORTS

COVID-19 pharmacotherapy utilization patterns during pregnancy: International Registry of Coronavirus Exposure in Pregnancy

Whitney J. Westhoff,  Louisa H. Smith,  Diego F. Wyszynski,  Sonia Hernandez-Diaz, 
  • Pages: 804-809
  • First Published: 14 April 2022

Trends in antipsychotic use for youth with attention-deficit/hyperactivity disorder and disruptive behavior disorders

Susan dosReis,  Jannat Saini,  Kyungwan Hong,  Gloria Reeves,  O' Mareen Spence, 
  • Pages: 810-814
  • First Published: 28 April 2022

CORRIGENDUM

Free Access

Corrigendum

  • Page: 815
  • First Published: 20 May 2022

ISSUE INFORMATION

Free Access

Issue Information

  • Page: 816
  • First Published: 07 June 2022